Results 41 to 50 of about 8,252,790 (324)
Key Points Question Are cancer drugs granted accelerated approval from the US Food and Drug Administration (FDA) recommended for funding through the National Health Service (NHS) in England?
Avi Cherla +4 more
semanticscholar +1 more source
Background The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focuses on diseases common in those ...
Rumiko Shimazawa, Masayuki Ikeda
doaj +1 more source
Trends in FDA drug approvals over last 2 decades: An observational study
Introduction: The discovery of novel drugs is critical for pharmaceutical research and development as well as for patient treatment. Repurposing existing drugs that may have anticipated effects as potential candidate is one way to meet this important ...
Angelika Batta +2 more
doaj +1 more source
Rare diseases affect over 25 million individuals in the United States and have historically lacked pharmaceutical development attention due to decreased potential for profit.
Wadhwa, Roopma, Roberts, Alexis-Danielle
core +1 more source
Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine +17 more
wiley +1 more source
The use of mechanistic evidence in drug approval
The role of mechanistic evidence tends to be under‐appreciated in current evidence‐based medicine (EBM), which focusses on clinical studies, tending to restrict attention to randomized controlled studies (RCTs) when they are available. The EBM+ programme
J. Aronson +4 more
semanticscholar +1 more source
Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz +12 more
wiley +1 more source
The importance of greater speed in drug development for advanced malignancies
It takes on average 6–12 years to develop new anticancer drugs from discovery to approval. Effective new agents prolong survival. To demonstrate the importance of rapid drug approval, we calculated life‐years potentially saved if selected agents were ...
David J. Stewart +9 more
doaj +1 more source
Therapeutic Advances in Duchenne Muscular Dystrophy: Regulatory Milestones, Emerging Modalities, and Implications for Clinical Practice [PDF]
Duchenne muscular dystrophy (DMD) is undergoing rapid therapeutic change, driven by mutation-specific treatments, gene-based interventions, and non-gene disease-modifying approaches.
Vivek Mundada
doaj +1 more source
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani +7 more
wiley +1 more source

